Email This Article
Headlines & Perspectives
Introgen's Advexin Doesn't Work. Period.
By
Adam Feuerstein
07/14/08 - 10:39 AM EDT
Last week's conference call did nothing to assure investors that the gene therapy drug for head and neck cancer can secure regulatory approval.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,422.83 | 1,114.59 | 2,236.22 | 36.53 |
Oil *
72.79
|
|
UP
93.94
|
UP
12.12
|
UP
24.53
|
UP
1.07
|
10 Yr
3.65%
SPDR Gold
107.06
|
|
+0.91%
|
+1.10%
|
+1.11%
|
+3.02%
|
Data delayed 20 minutes |
Connect with TheStreet